Industry

Late-Breaking presentation of phase 2 results from a clinical trial of GX-188E in combination with KEYTRUDA® (pembrolizumab) demonstrates anti-tumor benefit in heavily pre-treated, recurrent and advanced cervical cancer SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet … [Read more…]

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$bgne #beigene—BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conference: September 8, 2022 at 10:00 am CDT at the 2022 Wells Fargo Leveraged Finance Conference at the Gaylord Opryland Resort Hotel in Nashville, TN. A link to the live audio webcast, where applicable, and copies of any related presentation … [Read more…]

– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab – – Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 months with nivolumab combined with ipilimumab – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. … [Read more…]

– Results from EV-103 trial evaluating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) in urothelial cancer to be featured as late-breaking oral session – BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2022, to be held September 9-13 … [Read more…]

Not intended for US- or Canada-based media Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unresected LA SCCHN Initial results of Phase II INSIGHT 2 study of TEPMETKO plus osimertinib as second-line treatment in EGFR-mutant NSCLC with MET amplification showed encouraging signs … [Read more…]

— 3.2 Month Survival Benefit Demonstrated in Patients who had Already Received Prior Endocrine-based Therapy and at Least Two Prior Chemotherapies — — Trodelvy Now Shows a Survival Benefit in both Pre-treated HR+/HER2- Metastatic Breast Cancer and Second-Line Metastatic Triple-Negative Breast Cancer — FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced the positive … [Read more…]

2022 Pittsburgh Heart Walk supporting the American Heart Association sponsored by IDI Consulting PITTSBURGH–(BUSINESS WIRE)–#ITPittsburgh–IDI Consulting is a proud sponsor of the 2022 Pittsburgh Heart Walk happening on September 17th at Point State Park. Join IDI Consulting and other heroes in the community and walk together in the fight against heart disease and stroke. Donations … [Read more…]

Findings presented at the European Respiratory Society International Congress 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), are likely to have progressive disease that declines with combination immunosuppressive … [Read more…]

BOSTON–(BUSINESS WIRE)–Exaktera LLC, (“Exaktera”), a Union Park Capital (“Union Park”) portfolio company, is pleased to announce its acquisition of Advanced Illumination Inc. (“Advanced Illumination”), a long-established design and manufacturer of specialty LED lighting assemblies and drivers for machine vision, industrial imaging, bio-medical and related imaging applications. Terms of the transaction were not disclosed. Advanced Illumination’s … [Read more…]